182 related articles for article (PubMed ID: 18505050)
1. The role of regulatory T cells in malignant glioma.
Sonabend AM; Rolle CE; Lesniak MS
Anticancer Res; 2008; 28(2B):1143-50. PubMed ID: 18505050
[TBL] [Abstract][Full Text] [Related]
2. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.
Heimberger AB; Abou-Ghazal M; Reina-Ortiz C; Yang DS; Sun W; Qiao W; Hiraoka N; Fuller GN
Clin Cancer Res; 2008 Aug; 14(16):5166-72. PubMed ID: 18698034
[TBL] [Abstract][Full Text] [Related]
3. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors.
El Andaloussi A; Han Y; Lesniak MS
J Neurosurg; 2006 Sep; 105(3):430-7. PubMed ID: 16961139
[TBL] [Abstract][Full Text] [Related]
4. The role of regulatory T-cells in glioma immunology.
Ooi YC; Tran P; Ung N; Thill K; Trang A; Fong BM; Nagasawa DT; Lim M; Yang I
Clin Neurol Neurosurg; 2014 Apr; 119():125-32. PubMed ID: 24582432
[TBL] [Abstract][Full Text] [Related]
5. [Antitumor immune response: what are the roles for gliomas?].
Dietrich PY
Rev Neurol (Paris); 2001 Nov; 157(11 Pt 1):1339-48. PubMed ID: 11924003
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance and mechanism of Treg infiltration in human brain tumors.
Jacobs JF; Idema AJ; Bol KF; Grotenhuis JA; de Vries IJ; Wesseling P; Adema GJ
J Neuroimmunol; 2010 Aug; 225(1-2):195-9. PubMed ID: 20537408
[TBL] [Abstract][Full Text] [Related]
7. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.
Shen LS; Wang J; Shen DF; Yuan XL; Dong P; Li MX; Xue J; Zhang FM; Ge HL; Xu D
Clin Immunol; 2009 Apr; 131(1):109-18. PubMed ID: 19153062
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T cells and asthma.
Robinson DS
Clin Exp Allergy; 2009 Sep; 39(9):1314-23. PubMed ID: 19538496
[TBL] [Abstract][Full Text] [Related]
9. [Influence of high mobility group box-1 protein on the correlation between regulatory T cells and CD4+ CD25- T cells of spleen in mice].
Zhang Y; Yao YM; Yu Y; Wu Y; Sheng ZY
Zhonghua Wai Ke Za Zhi; 2008 Feb; 46(3):217-20. PubMed ID: 18683721
[TBL] [Abstract][Full Text] [Related]
10. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg.
Biollaz G; Bernasconi L; Cretton C; Püntener U; Frei K; Fontana A; Suter T
Eur J Immunol; 2009 May; 39(5):1323-33. PubMed ID: 19337997
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of the immunosuppressive mechanism in patients with malignant brain tumors].
Yoshida S
No To Shinkei; 1985 Dec; 37(12):1137-43. PubMed ID: 3879181
[TBL] [Abstract][Full Text] [Related]
12. Local Application of Autologous Platelet-Rich Fibrin Patch (PRF-P) Suppresses Regulatory T Cell Recruitment in a Murine Glioma Model.
Panek WK; Pituch KC; Miska J; Kim JW; Rashidi A; Kanojia D; Lopez-Rosas A; Han Y; Yu D; Chang CL; Kane JR; Zhang P; Cordero A; Lesniak MS
Mol Neurobiol; 2019 Jul; 56(7):5032-5040. PubMed ID: 30460615
[TBL] [Abstract][Full Text] [Related]
13. Cell- and peptide-based immunotherapeutic approaches for glioma.
Yamanaka R
Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
[TBL] [Abstract][Full Text] [Related]
14. Function of CD4+,CD25+ Treg cells in MRL/lpr mice is compromised by intrinsic defects in antigen-presenting cells and effector T cells.
Parietti V; Monneaux F; Décossas M; Muller S
Arthritis Rheum; 2008 Jun; 58(6):1751-61. PubMed ID: 18512811
[TBL] [Abstract][Full Text] [Related]
15. Regulatory CD4+CD25+ T cells and macrophages: communication between two regulators of effector T cells.
Zhen Y; Zheng J; Zhao Y
Inflamm Res; 2008 Dec; 57(12):564-70. PubMed ID: 19109736
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for human glioma: innovative approaches and recent results.
Hussain SF; Heimberger AB
Expert Rev Anticancer Ther; 2005 Oct; 5(5):777-90. PubMed ID: 16221048
[TBL] [Abstract][Full Text] [Related]
17. In vitro suppression of xenoimmune-mediated macrophage activation by human CD4+CD25+ regulatory T cells.
Fu Y; Yi S; Wu J; Jimenez E; Simond D; Hawthorne WJ; O'Connell PJ
Transplantation; 2008 Sep; 86(6):865-74. PubMed ID: 18813112
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell-based immunotherapy for malignant gliomas.
Akasaki Y; Black KL; Yu JS
Expert Rev Neurother; 2005 Jul; 5(4):497-508. PubMed ID: 16026233
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of local immunoresistance in glioma.
Albesiano E; Han JE; Lim M
Neurosurg Clin N Am; 2010 Jan; 21(1):17-29. PubMed ID: 19944963
[TBL] [Abstract][Full Text] [Related]
20. Monitoring immune responses after glioma vaccine immunotherapy.
Jian B; Yang I; Parsa AT
Neurosurg Clin N Am; 2010 Jan; 21(1):195-9. PubMed ID: 19944978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
